Advertisement
AXON vs KROS
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Keros Therapeutics (KROS) Stock Comparison
Key Takeaways
- AXON is an established public-safety technology leader with over $2.9 billion in trailing revenue and a market capitalization near $42 billion, while KROS is a clinical-stage biotech with a roughly $200 million market cap and no approved products.
- Axon has delivered seven consecutive quarters of 30%-plus revenue growth but faces margin compression and a significant valuation reset, with its stock down roughly 29% over the past year.
- Keros Therapeutics recognized substantial one-time licensing revenue from its Takeda partnership in 2025, but forward revenue has normalized sharply as milestone-dependent economics take over.
- Both stocks carry elevated risk profiles: AXON contends with hardware tariff headwinds and profitability questions, while KROS faces binary clinical-trial outcomes and uncertain revenue visibility.
- Axon offers recurring SaaS (Software-as-a-Service) revenue and a diversified product ecosystem; Keros offers deep-value balance-sheet attributes with a catalyst-rich pipeline ahead.
- Investor sentiment toward AXON remains cautiously constructive, backed by record bookings, while sentiment around KROS hinges on clinical execution and milestone timing.
Introduction
Comparing Axon Enterprise (AXON) and Keros Therapeutics (KROS) is a study in contrasts: one is a dominant, revenue-generating force in public-safety hardware and cloud software, while the other is a pre-revenue biopharmaceutical company navigating the high-risk, high-reward world of drug development. These two stocks occupy entirely different sectors, market-cap tiers, and stages of corporate maturity. Yet both are drawing significant attention from traders and investors seeking differentiated exposure — AXON for its AI-enhanced law-enforcement ecosystem, and KROS for its clinical pipeline targeting disorders tied to TGF-ß (transforming growth factor-beta) protein signaling. This comparison provides a framework for evaluating relative momentum, risk factors, and positioning in the current market environment.
AXON Overview and Recent Performance
Axon Enterprise develops and sells conducted-energy devices under the TASER brand, body-worn and in-car cameras, digital-evidence management software, drones, and VR (virtual reality) training tools. The company serves law enforcement, military, and commercial customers worldwide. Over recent quarters, AXON has sustained remarkable top-line momentum — revenue grew 33.5% year-over-year for full-year 2025, reaching approximately $2.78 billion, while the Software & Services segment expanded 41% and annual recurring revenue (ARR) crossed $1.3 billion with a net revenue retention rate of 124%. Fourth-quarter 2025 results exceeded consensus expectations, with revenue of $797 million and adjusted EPS (earnings per share) of $2.15. However, the stock has undergone a significant valuation compression. After peaking near $886 in 2025, shares retreated roughly 40% over a six-month span, reflecting investor concerns about margin erosion — trailing net profit margin compressed to approximately 4.5% — tariff-related hardware cost pressures, and the cost of integrating major acquisitions including Carbyne and Prepared. In recent weeks, trading has been volatile, with the stock oscillating between approximately $485 and $665. For 2026, management has guided to 27–30% revenue growth and an adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin of 25.5%, with a long-term target of $6 billion in annual revenue by 2028.
KROS Overview and Recent Performance
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on novel protein-therapeutic candidates that target dysfunctional TGF-ß signaling, with applications across hematological, musculoskeletal, and neuromuscular disorders. The company's lead wholly owned asset, rinvatercept (KER-065), is advancing toward a Phase 2 clinical trial in Duchenne muscular dystrophy (DMD), with regulatory engagement for an ALS (amyotrophic lateral sclerosis) trial expected later in 2026. Its most advanced candidate, elritercept, has been partnered with Takeda, which plans to advance the drug into a Phase 3 trial for myelodysplastic syndromes. On paper, 2025 was a transformative year: KROS reported $244.1 million in total revenue and net income of $87 million, driven largely by a $200 million upfront payment and milestone recognition from Takeda. However, those figures are non-recurring. Trailing twelve-month revenue has since normalized to approximately $33 million, and the company has returned to posting net losses. The stock has reflected this dynamic, trading recently around $10 per share — near the low end of its 52-week range of $9.69 to $22.55 — with a market capitalization of roughly $200 million. On the positive side, Keros ended 2025 with $287.4 million in cash and executed a $375 million capital-return program that reduced shares outstanding to approximately 19.5 million. Trading at roughly 0.7x book value, the stock draws attention as a deep-value biotech play, albeit one dependent on clinical catalysts for rerating.
Trending AI Robots
In a market environment where speed, pattern recognition, and disciplined risk management increasingly separate outcomes, Tickeron's Trending AI Robots page offers a curated window into the platform's most relevant AI-driven trading strategies. Tickeron hosts hundreds of AI Trading Bots spanning thousands of tickers, each with distinct trading styles, timeframes — from 5-minute to daily — and performance profiles. Annualized returns among top-performing bots have reached well into the double and triple digits in recent periods, with win rates frequently exceeding 60% and in select cases approaching 90%. Profit factors above 2.0 and even 4.0 have been observed, meaning that for every dollar risked, the AI has generated two to four dollars in return. Only the bots best suited to prevailing market conditions earn a spot in the Trending section, making it a dynamic showcase of what adaptive, machine-learning-driven trading can achieve across diverse sectors and volatility regimes. Explore the current lineup at Trending AI Robots.
Head-to-Head Comparison
From a business-model standpoint, the divide between these two companies is stark. AXON operates a proven razor-and-blade model: hardware sales create an installed base that drives high-margin, recurring software subscriptions. Its diversified product line — TASER devices, body cameras, fleet systems, drones, and VR training — serves a customer base anchored by government and law enforcement agencies with relatively predictable budget cycles. In contrast, KROS generates no product revenue and depends entirely on partner milestones, licensing economics, and clinical-trial success to create value.
On the growth-driver front, AXON is expanding its total addressable market through AI-powered software (including the AI Era Plan, its fastest-booked product) and the Axon 911 platform. KROS has its growth bets concentrated in clinical data readouts and regulatory progress for rinvatercept. The risk profiles diverge accordingly: Axon's risks center on execution — margin compression, tariff exposure, and sustaining premium valuation multiples — while Keros faces binary risk where negative trial results could materially impair the investment thesis.
Market sentiment reflects these contrasts. Axen's analyst consensus remains a "Strong Buy" with a mean price target implying significant upside from recent levels, though insider selling activity has raised eyebrows. Keros carries a consensus "Buy" rating with a price target roughly double its current price, but the wide dispersion between target and actual share price underscores the market's uncertainty around clinical outcomes. In sector terms, AXON benefits from consistent governmental demand tailwinds, while KROS faces the inherent volatility of the biotechnology sector, where sentiment can pivot sharply on a single data release.
Tickeron AI Verdict
Based on observable factors such as trend consistency, revenue visibility, and relative stability of catalysts, Tickeron's AI-driven analysis would likely favor AXON in the current environment. Axon's recurring SaaS revenue base, expanding ARR, and record bookings momentum — full-year 2025 bookings grew 46% to $7.4 billion — provide a more quantifiable and trend-persistent foundation than Keros's milestone-dependent and non-recurring revenue structure. While KROS offers an intriguing deep-value setup with a cash-rich balance sheet and multiple upcoming catalysts, the stock's recent drift toward 52-week lows and lack of near-term recurring revenue make it a higher-probability candidate for continued choppiness. That said, AI models assess probabilities, not certainties, and Keros's compressed valuation relative to book value could register as a mean-reversion signal under a different strategic lens. In a head-to-head context emphasizing trend reliability and business-model durability, Axon's characteristics align more closely with what adaptive algorithms tend to favor in the present market regime.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Hold and KROS is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 1 FA rating(s) are green whileKROS’s FA Score has 0 green FA rating(s).
- AXON’s FA Score: 1 green, 4 red.
- KROS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while KROS’s TA Score has 3 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 4 bearish.
- KROS’s TA Score: 3 bullish, 6 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а +5.06% price change this week, while KROS (@Biotechnology) price change was +0.10% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +5.98%. For the same industry, the average monthly price growth was -12.27%, and the average quarterly price growth was -7.58%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.22%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +2790.29%.
Reported Earning Dates
AXON is expected to report earnings on Aug 05, 2026.
KROS is expected to report earnings on Aug 12, 2026.
Industries' Descriptions
@Aerospace & Defense (+5.98% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (-1.22% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | KROS | AXON / KROS | |
| Capitalization | 42.5B | 199M | 21,357% |
| EBITDA | 320M | -108.78M | -294% |
| Gain YTD | -7.073 | -50.540 | 14% |
| P/E Ratio | 212.81 | 4.78 | 4,454% |
| Revenue | 2.98B | 33.2M | 8,985% |
| Total Cash | 737M | 281M | 262% |
| Total Debt | 1.83B | 16.3M | 11,215% |
AXON | KROS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 47 Fair valued | |
PROFIT vs RISK RATING 1..100 | 62 | 100 | |
SMR RATING 1..100 | 82 | 96 | |
PRICE GROWTH RATING 1..100 | 52 | 77 | |
P/E GROWTH RATING 1..100 | 33 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KROS's Valuation (47) in the null industry is somewhat better than the same rating for AXON (89) in the Biotechnology industry. This means that KROS’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (62) in the Biotechnology industry is somewhat better than the same rating for KROS (100) in the null industry. This means that AXON’s stock grew somewhat faster than KROS’s over the last 12 months.
AXON's SMR Rating (82) in the Biotechnology industry is in the same range as KROS (96) in the null industry. This means that AXON’s stock grew similarly to KROS’s over the last 12 months.
AXON's Price Growth Rating (52) in the Biotechnology industry is in the same range as KROS (77) in the null industry. This means that AXON’s stock grew similarly to KROS’s over the last 12 months.
AXON's P/E Growth Rating (33) in the Biotechnology industry is significantly better than the same rating for KROS (100) in the null industry. This means that AXON’s stock grew significantly faster than KROS’s over the last 12 months.
| AXON | KROS | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 61% | N/A |
| Stochastic ODDS (%) | 4 days ago 82% | 4 days ago 83% |
| Momentum ODDS (%) | 4 days ago 83% | 4 days ago 70% |
| MACD ODDS (%) | 4 days ago 72% | 4 days ago 70% |
| TrendWeek ODDS (%) | 4 days ago 76% | 4 days ago 77% |
| TrendMonth ODDS (%) | 4 days ago 71% | 4 days ago 77% |
| Advances ODDS (%) | 7 days ago 74% | 26 days ago 76% |
| Declines ODDS (%) | 5 days ago 70% | 6 days ago 76% |
| BollingerBands ODDS (%) | 5 days ago 61% | 4 days ago 85% |
| Aroon ODDS (%) | 4 days ago 79% | 4 days ago 83% |
Advertisement
KROS and
Correlation & Price change
A.I.dvisor indicates that over the last year, KROS has been loosely correlated with MGTX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then MGTX could also see price increases.
| Ticker / NAME | Correlation To KROS | 1D Price Change % | ||
|---|---|---|---|---|
| KROS | 100% | -1.47% | ||
| MGTX - KROS | 44% Loosely correlated | -1.59% | ||
| AXON - KROS | 43% Loosely correlated | +0.47% | ||
| SANA - KROS | 42% Loosely correlated | -3.69% | ||
| VIR - KROS | 42% Loosely correlated | -2.70% | ||
| IMVT - KROS | 42% Loosely correlated | -2.18% | ||
More | ||||